Oh, I can't believe we are now almost 50% of the cash reserve.Can't think of any better opportunity of major shareholders and directors to show their hands @ current price.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%
